MA47697A - Inhibiteurs de l'(alpha-v)(bêta-6) intégrine - Google Patents

Inhibiteurs de l'(alpha-v)(bêta-6) intégrine

Info

Publication number
MA47697A
MA47697A MA047697A MA47697A MA47697A MA 47697 A MA47697 A MA 47697A MA 047697 A MA047697 A MA 047697A MA 47697 A MA47697 A MA 47697A MA 47697 A MA47697 A MA 47697A
Authority
MA
Morocco
Prior art keywords
integrin
inhibitors
beta
alpha
inhibitors integrin
Prior art date
Application number
MA047697A
Other languages
English (en)
Inventor
Mark Brewer
Matthew Gregory Bursavich
Aleksey Lgorevich Gerasyuto
Kristopher Neil Hahn
Bryce Alden Harrison
Kyle David Konze
fu-yang Lin
Blaise Scott Lippa
Alexey Alexandrovich Lugovskoy
Bruce Nelsen Rogers
Mats Ake Svensson
Dawn Marie Troast
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of MA47697A publication Critical patent/MA47697A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA047697A 2017-02-28 2018-02-27 Inhibiteurs de l'(alpha-v)(bêta-6) intégrine MA47697A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762464693P 2017-02-28 2017-02-28

Publications (1)

Publication Number Publication Date
MA47697A true MA47697A (fr) 2020-01-08

Family

ID=63245635

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047697A MA47697A (fr) 2017-02-28 2018-02-27 Inhibiteurs de l'(alpha-v)(bêta-6) intégrine

Country Status (16)

Country Link
US (5) US11040955B2 (fr)
EP (2) EP4159727B1 (fr)
JP (2) JP7092784B2 (fr)
KR (2) KR102605460B1 (fr)
CN (2) CN116283977B (fr)
AR (2) AR111009A1 (fr)
AU (4) AU2018229275B2 (fr)
BR (1) BR112019017929A2 (fr)
CA (1) CA3054604A1 (fr)
IL (3) IL316954A (fr)
MA (1) MA47697A (fr)
MX (2) MX394210B (fr)
RU (2) RU2769702C2 (fr)
SG (1) SG11201907820SA (fr)
TW (2) TWI834321B (fr)
WO (1) WO2018160521A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3509590A4 (fr) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. Composés d'acides aminés n-acyle et méthodes d'utilisation
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
MX394210B (es) 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
FI3761980T3 (fi) 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
WO2020047207A1 (fr) * 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
SI3844162T1 (sl) * 2018-08-29 2025-06-30 Morphic Therapeutic, Inc. Zaviralci integrina alfa v beta6
WO2020047239A1 (fr) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITION DE L'INTÉGRINE ανβ6
WO2020047208A1 (fr) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3873605B1 (fr) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Composés pour inhibition de l'intégrine alpha4beta7
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
FI3873884T3 (fi) 2018-10-30 2025-02-24 Gilead Sciences Inc 3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
CN114173803A (zh) 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
WO2021030438A1 (fr) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Composés pour l'inhibition de l'intégrine alpha 4 bêta 7
TWI775182B (zh) * 2019-10-16 2022-08-21 美商莫菲克醫療股份有限公司 抑制人類整合素αβ
CN111718250B (zh) * 2020-06-28 2022-04-22 万华化学集团股份有限公司 一种制备r-香茅醛的方法
EP4247472A4 (fr) 2020-11-19 2024-10-09 Pliant Therapeutics, Inc. Inhibiteur d'intégrine et ses utilisations
JP2026506655A (ja) * 2023-02-14 2026-02-25 モーフィック セラピューティック，インコーポレイテッド αｖβ８インテグリンの阻害
JP2026506652A (ja) * 2023-02-14 2026-02-25 モーフィック セラピューティック，インコーポレイテッド αｖβ８インテグリンの阻害
WO2025106644A1 (fr) * 2023-11-15 2025-05-22 Morphic Therapeutic, Inc. Composés hétérocycliques utilisés en tant qu'inhibiteurs de l'intégrine alpha-v bêta-1

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW221996B (fr) * 1991-11-14 1994-04-01 Glaxo Group Ltd
AU3351293A (en) 1992-01-21 1993-08-03 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
DK0623615T3 (da) 1993-05-01 1999-12-13 Merck Patent Gmbh Adhæsionsreceptor-antagonister
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
WO1997024122A1 (fr) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Antagonistes du recepteur de vitronectine
CZ203898A3 (cs) * 1995-12-29 1999-03-17 Smithkline Beecham Corporation Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití
US20010034445A1 (en) 1995-12-29 2001-10-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
AU713676B2 (en) 1996-01-16 1999-12-09 Merck & Co., Inc. Integrin receptor antagonists
ES2171768T3 (es) 1996-03-20 2002-09-16 Hoechst Ag Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
HUP9902455A3 (en) * 1996-03-29 2000-06-28 Pfizer 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them
JP2002511052A (ja) * 1996-08-29 2002-04-09 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
US5952341A (en) * 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
WO1998018460A1 (fr) * 1996-10-30 1998-05-07 Merck & Co., Inc. Antagonistes de l'integrine
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
AU7105498A (en) 1997-04-14 1998-11-11 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
CA2309204A1 (fr) 1997-11-26 1999-06-03 Dupont Pharmaceuticals Company 1,3,4-thiadiazoles et 1,3,4-oxadiazoles utilises comme antagonistes de .alpha.v.beta.3
CA2315370A1 (fr) 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
CA2315232A1 (fr) 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
KR20010033248A (ko) 1997-12-17 2001-04-25 폴락 돈나 엘. 인테그린 수용체 길항제
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
EA003095B1 (ru) 1997-12-17 2002-12-26 Мерк Энд Ко., Инк. Антагонисты рецепторов интегринов
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO2000006169A1 (fr) 1998-07-29 2000-02-10 Merck & Co., Inc. Antagonistes des recepteurs de l'integrine
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
CZ20012212A3 (cs) 1998-12-19 2001-09-12 Merck Patent Gmbh Peptidická sloučenina, její použití a farmaceutický prostředek, který ji obsahuje
AU747503B2 (en) * 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
CN1589145A (zh) 1999-06-02 2005-03-02 麦克公司 αv整联蛋白受体拮抗剂
WO2000078317A1 (fr) 1999-06-23 2000-12-28 Merck & Co., Inc. Antagonistes des recepteurs de l'integrine
DE19933173A1 (de) 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
GB9929988D0 (en) 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
CA2397194C (fr) 2000-01-20 2011-05-17 Mark E. Duggan Antagonistes du recepteur de l'integrine alpha v
CA2397665A1 (fr) 2000-01-24 2001-07-26 Merck & Co., Inc. Antagonistes du recepteur de l'integrine alpha v
US7119098B2 (en) 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
WO2002022616A2 (fr) 2000-09-14 2002-03-21 Merck & Co., Inc. Antagonistes du recepteur des integrines alpha v
WO2002022615A1 (fr) 2000-09-14 2002-03-21 Merck & Co., Inc. Antagonistes du recepteur de l'alpha v integrine
EP1322311A1 (fr) 2000-09-18 2003-07-02 Merck & Co., Inc. Traitement de l'inflammation au moyen d'une combinaison d'un inhibiteur de cyclooxygenase-2 et d'un antagoniste d'integrine alpha-v
CA2436130A1 (fr) 2001-01-29 2002-08-08 Ortho-Mcneil Pharmaceutical, Inc. Indoles substitues et utilisation de ceux-ci comme antagonistes d'integrine
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
WO2002090325A2 (fr) 2001-05-03 2002-11-14 Merck & Co., Inc. Benzazepinones, antagonistes de recepteur d'integrine alpha v
US20040043988A1 (en) 2001-06-15 2004-03-04 Khanna Ish Kurmar Cycloalkyl alkanoic acids as intergrin receptor antagonists
DE10204789A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
AU2003259891A1 (en) 2002-08-16 2004-03-19 Janssen Pharmaceutica N.V. Piperidinyl compounds that selectively bind integrins
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
JP2009539815A (ja) 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
CN101784516B (zh) 2007-06-13 2014-07-02 百时美施贵宝公司 作为凝血因子抑制剂的二肽类似物
AU2008321770B2 (en) * 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
US20120289481A1 (en) 2011-05-13 2012-11-15 O'neil Jennifer Compositions and methods for treating cancer
WO2014015054A1 (fr) * 2012-07-18 2014-01-23 Saint Louis University Dérivés d'acides bêta aminés en tant qu'antagonistes d'intégrine
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
EP2784511A1 (fr) 2013-03-27 2014-10-01 Universität Zürich Intégrine alpha-v-beta6 pour le diagnostic/pronostic du carcinome colorectal
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
US10533044B2 (en) 2014-01-06 2020-01-14 The General Hospital Corporation Integrin Antagonists
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2015179823A2 (fr) 2014-05-23 2015-11-26 The California Institute For Biomedical Research Inhibiteurs d'alpha (v) bêta 6, localisés dans les poumons
WO2016022851A1 (fr) 2014-08-06 2016-02-11 Children's Medical Center Corporation Polypeptides d'intégrine modifiés, dimères de polypeptides d'intégrine modifiés, et leurs utilisations
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
US9790222B2 (en) 2015-02-19 2017-10-17 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
BR112017020484B1 (pt) 2015-03-25 2023-03-28 Fujifilm Corporation Métodos para fabricar um composto contendo nitrogênio ou sal do mesmo e um complexo metálico, compostos contendo nitrogênio, complexos dos ditos compostos e composições farmacêuticas compreendendo os ditos complexos
BR112017023432A2 (pt) 2015-04-30 2018-07-24 Scifluor Life Sciences Inc Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo
SG11201805387RA (en) 2015-12-30 2018-07-30 Univ Saint Louis Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
US11192889B2 (en) 2016-07-05 2021-12-07 The Rockefeller University Tetrahydronaphthyridinepentanamide integrin antagonists
EP3509590A4 (fr) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. Composés d'acides aminés n-acyle et méthodes d'utilisation
SI3535397T1 (sl) 2016-11-01 2022-04-29 Arrowhead Pharmaceuticals, Inc. Ligandi alfa-V beta-6 integrina in njihove uporabe
WO2018085578A1 (fr) 2016-11-02 2018-05-11 Saint Louis University Inhibiteurs de l'intégrine en combinaison avec un agent qui interagit avec un récepteur de chimiokine
WO2018085552A1 (fr) 2016-11-02 2018-05-11 Saint Louis University Antagonistes de l'intégrine
HRP20210228T1 (hr) 2016-11-08 2021-03-19 Bristol-Myers Squibb Company Amidi pirola kao inhibitori alfa v integrina
WO2018089357A1 (fr) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company DÉRIVÉS D'INDAZOLE EN TANT QU'ANTAGONISTES DE L'INTÉGRINE αV
AU2017359023B2 (en) 2016-11-08 2021-12-09 Bristol-Myers Squibb Company 3-substituted propionic acids as alpha v integrin inhibitors
BR112019009245A2 (pt) 2016-11-08 2019-07-16 Bristol-Myers Squibb Company azol amidas e aminas como inibidores de alfav integrina
ES2984394T3 (es) 2016-11-08 2024-10-29 Bristol Myers Squibb Co Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11306084B2 (en) 2016-12-29 2022-04-19 Saint Louis University Integrin antagonists
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
MX394210B (es) 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
FI3761980T3 (fi) 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
US20210284638A1 (en) 2018-07-03 2021-09-16 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS
WO2020047239A1 (fr) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITION DE L'INTÉGRINE ανβ6
WO2020047208A1 (fr) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
SI3844162T1 (sl) 2018-08-29 2025-06-30 Morphic Therapeutic, Inc. Zaviralci integrina alfa v beta6
WO2020047207A1 (fr) 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CN114173803A (zh) 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案

Also Published As

Publication number Publication date
CN110573499A (zh) 2019-12-13
KR20230163575A (ko) 2023-11-30
AU2024201414B2 (en) 2026-03-05
RU2769702C2 (ru) 2022-04-05
MX2019010267A (es) 2020-02-05
AR111009A1 (es) 2019-05-22
KR20190133682A (ko) 2019-12-03
US20200087299A1 (en) 2020-03-19
AU2026201633A1 (en) 2026-03-26
US20240327378A1 (en) 2024-10-03
AR125414A2 (es) 2023-07-12
US20200157075A1 (en) 2020-05-21
CN110573499B (zh) 2023-04-21
US20180244648A1 (en) 2018-08-30
SG11201907820SA (en) 2019-09-27
EP4159727A1 (fr) 2023-04-05
MX2022009056A (es) 2022-08-15
IL297530B1 (en) 2024-12-01
JP2020510664A (ja) 2020-04-09
WO2018160521A2 (fr) 2018-09-07
US12415796B2 (en) 2025-09-16
RU2019130492A3 (fr) 2021-04-15
AU2018229275B2 (en) 2021-12-23
RU2022108080A (ru) 2022-04-07
EP4159727B1 (fr) 2026-04-08
JP7443425B2 (ja) 2024-03-05
JP7092784B2 (ja) 2022-06-28
IL297530A (en) 2022-12-01
RU2019130492A (ru) 2021-03-30
EP3589627A2 (fr) 2020-01-08
AU2022201908B2 (en) 2024-03-21
IL297530B2 (en) 2025-04-01
IL316954A (en) 2025-01-01
US11040955B2 (en) 2021-06-22
IL268947A (en) 2019-10-31
KR102605460B1 (ko) 2023-11-22
US20210276975A1 (en) 2021-09-09
CN116283977A (zh) 2023-06-23
TW201835078A (zh) 2018-10-01
TWI834321B (zh) 2024-03-01
AU2024201414A1 (en) 2024-03-21
US11827621B2 (en) 2023-11-28
US11046669B2 (en) 2021-06-29
BR112019017929A2 (pt) 2020-05-19
AU2018229275A1 (en) 2019-09-19
CA3054604A1 (fr) 2018-09-07
CN116283977B (zh) 2026-02-10
TW202325707A (zh) 2023-07-01
MX394210B (es) 2025-03-04
EP3589627A4 (fr) 2020-08-05
AU2022201908A1 (en) 2022-04-07
JP2022120159A (ja) 2022-08-17
KR102891803B1 (ko) 2025-11-28
WO2018160521A3 (fr) 2018-10-11

Similar Documents

Publication Publication Date Title
MA47697A (fr) Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
EP3843728A4 (fr) Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
EP3843727A4 (fr) Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
MA47692A (fr) Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
EP3701819A4 (fr) Générateur d'aérosol
EP3679813A4 (fr) Dispositif de production d'aérosol
EP3635724A4 (fr) Techniques de suivi d'objet
EP3704971A4 (fr) Dispositif de génération d'aérosol
EP3704964A4 (fr) Dispositif de génération d'aérosol
EP3607587A4 (fr) Panneau d'affichage
EP3610741A4 (fr) Dispositif de génération d'aérosol
EP3860977A4 (fr) Antagonistes de l'intégrine
EP3729135C0 (fr) Suivi d'objets
EP3384301A4 (fr) Surveillance d'ondulation
EP3481814A4 (fr) Antagonistes de l'intégrine tetrahydronaphthyridinepentanamide
EP3394754A4 (fr) Planification d'applications fortement parallèles
MA49006A (fr) Inhibiteurs d'ip6k
EP3729982A4 (fr) Dispositif de génération d'aérosol
EP3689999A4 (fr) Pulvérisateur
EP3477349A4 (fr) Dispositif d'enlèvement de revêtement
PL3613739T3 (pl) Antagoniści integryn
MA47226A (fr) Reconstituant de sol
EP3275817A4 (fr) Dispositif d'accumulation
EP3573458A4 (fr) Systèmes de récipient de tissu
DK3385339T3 (da) Vandige overtræksstoffer